Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
NCT ID: NCT04445610
Last Updated: 2020-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2020-07-01
2020-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measles Vaccine in HCW
NCT04357028
Measles Vaccination at Health System Contacts
NCT04220671
A Second Dose of Measles Vaccine (MV) in the Second Year of Life
NCT02943681
Additional Measles Vaccine at 4 Months of Age
NCT01486355
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
NCT00891007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To identify Measles IgG titre in SARS-COV2 infected patients .
2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease.
Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection
Criteria:
Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate \& severe)
* All patients with confirmed COVID 19 confirmed by positive PCR . .
* Any age or gender.
Exclusion criteria:
\- Any patient refusing to be involved in the study.
Methods:
* Informed consent will be taken from each subject
* Full clinical examination.
* Evaluation of Measles Antibody Titer:
The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin).
\- Anonymous data will be retrieved from the admitted patients' files, such as:
* CBC, CRP, AST, ALT, ESR, Serum ferritin \& SARS CoV 2 RNA PCR swab results.
* Chest X ray and/or CT chest.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
mild
No interventions assigned to this group
B
moderate
No interventions assigned to this group
C
severe
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any age or gender
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amira Al Balakosy
Tropical Medicine Department. Ain Shams University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amira Al Balakosy, M.D
Role: PRINCIPAL_INVESTIGATOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
Cairo, Non-US, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU P31a/ 2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.